Tutkimustuotoksia vuodessa
Tutkimustuotoksia vuodessa
PL 20 (Tukholmankatu 8)
00014
Suomi
Suomi
Viikinkaari 5, Biocenter 2
00790 Helsinki
Suomi
Tutkimustuotoksia vuodessa
My group is focused on understanding pathogenic and drug resistance mechanisms in hematological malignancies. Working closely with the clinic, we apply research tools to patient samples for better understanding of inter- and intra-disease heterogeneity and translation of basic research findings to patient care.
Although precision treatment strategies have been achieved with cancers such as chronic myeloid leukemia, which develop and can be targeted through a single driver event, most cancers are extremely heterogeneous and result from complex genetic changes. Thus, newer, targeted therapies often have limited efficacy in broader patient populations, or the duration of response is short, as drug resistant subclones are selected for and eventually cause disease recurrence. Future cancer drug development is therefore dependent on being able to identify responding and non-responding patients, and effectively monitor and change treatment as the patient’s disease evolves.
For our research, we use a systems-wide approach to analyze samples from individual patients diagnosed with a hematological malignancy. By combining genomic, transcriptomic, proteomic and functional ex vivo drug sensitivity testing of the patient’s tumor cells and comparing these data to that of normal cells, we get a broad view of genomic and phenotypic changes that have occurred in the tumor and which could potentially be therapeutically targeted. In addition, we analyze samples acquired at different stages of the patient’s disease (e.g. diagnosis, during treatment response and relapse) for better insight of disease progression mechanisms and understanding the impact of therapy on the patient’s tumor. Working closely with the FIMM Technology Centre and our collaborators, we quickly return our results to the clinic to maximize the amount of data available for guiding treatment decision of patients with relapsed or refractory disease.
EDUCATION
1996 PhD, Cancer Biology Program, University of Texas Health Science Center Houston, MD Anderson Cancer Center, Graduate School of Biomedical Sciences, Houston, Texas, USA (https://gsbs.uth.edu)
1989 BA, Biological Sciences, 1989, University of Chicago, Biological Sciences, Chicago, Illinois, USA (http://college.uchicago.edu)
CURRENT POSITIONS
2020 – now Research Director, Institute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland
2020 – 2022 Senior Researcher, Sigrid Jusélius Foundation, Finland
2010 – now Group Leader, Senior Researcher, Institute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland
2012 – now Principal Investigator, Medicum, Faculty of Medicine, University of Helsinki, Finland
PREVIOUS POSITIONS
2004 – 2010 Senior Researcher, Molecular/Cancer Biology Laboratory, University of Helsinki, Finland
2001 – 2004 Research Associate/Senior Researcher, Stanford University School of Medicine, Department of Medicine, Division of Hematology, Stanford, California, USA
1996 – 2004 Postdoctoral Researcher, Stanford University School of Medicine, Department of Medicine, Division of Hematology, Stanford, California, USA
FELLOWSHIPS AND AWARDS
Academy of Finland, American Association for Cancer Research, American Society of Hematology, American Thoracic Society, Cancer Society of Finland, Henzl-Gabor Fellowship for Women in Science, The LAM Foundation, Pulmonary Association Heli, Sigrid Jusélius Foundation, University of Helsinki Business Collaborator of the Year, Väinö and Laina Kivi Foundation
SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS
2010 – now 12 Postdoctoral Researchers, 12 PhD Students, 7 Master's Students, Institute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Finland
TEACHING ACTIVITIES
2018 – now Lecturer – Cancer Biology Course, TRANSMED Master's Program, University of Helsinki
2015 Lecturer – Cancer Race Course, Doctoral Program in Biomedicine, University of Helsinki
2014, 2018 Organizer – “Innovate, Protect and Spin It Off” Course, University of Helsinki
2012 – 2017 Seminar & Practical Writing Skills Course, University of Helsinki
INSTITUTIONAL RESPONSIBILITIES
2018 – 2020 Member of the Steering Group for University Business Collaboration and Innovation, University of Helsinki, Finland
2017 – now Member of the Doctoral Training Committee, Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Finland
2016 – now Principal Investigator of the Meilahti Integrated Biobank Infrastructure, Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Finland
2015 – now Member of the Doctoral Thesis Committee, 2 students, University of Helsinki, Finland
2015 – now Member of the Advisory Committee for the FIMM Postdoctoral Association, Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Finland
2012 – now Member of the Steering Group, Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Finland
2011 – now Member of the Working Group for the Finnish Hematology Registry and Biobank, Finland
REVIEWING ACTIVITES
Review panel member: Research Council of Norway, Foundation for Strategic Research Sweden, Swedish Research Council, Vienna Science and Technology Fund
External reviewer: Wellcome Trust UK, University of Eastern Finland, Swiss Cancer League
Doctoral dissertation opponent: Yanara Marincevic-Zuniga, Uppsala University, Sweden (2018); Chinh Bkrong Nguyen, University of Oslo, Norway (2018)
Doctoral dissertation examination committee member: Johan Lund, Karolinska Institute, Sweden (2017)
Advisory board member: Blood Cancer Network Ireland (2016-now)
Editorial review board member: Journal of Personalized Medicine
Manuscripts: >25 scientific journals including Blood, Cancer Research, Clinical Cancer Research, Genome Research, Haematologica, Leukemia, Molecular Cancer Therapeutics, New England Journal of Medicine, Molecular and Cellular Biology, Oncogene
Abstract reviewer for international conferences: American Society of Hematology Annual Meeting, European Hematology Association Annual Congress
MEMBERSHIPS OF SCIENTIFIC SOCIETIES
American Association for Cancer Research, American Society of Hematology, European Hematology Association, European School of Hematology, Nordic Myeloma Study Group
POSITIONS OF TRUST
Executive board member: European Patients' Academy on Therapeutic Innovation (EUPATI) - Finland (2018-now)
AREAS OF EXPERTISE
Hematological malignancies, molecular oncology, precision medicine, genomic and transcriptomic analyses, next generation sequencing, high throughput screening, translational cancer research, systems biology, biobanking
PUBLICATIONS
Number of original research articles in refereed scientific journals: 60
Number of original contributions to refereed scientific conferences: 140
Number of review articles and book chapters: 4
h-index: 25
i10-index: 39
Web address to list of publications:
Tutkimustuotos: Artikkelijulkaisu › Kirje › Tieteellinen › vertaisarvioitu
Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu
Tutkimustuotos: Artikkelijulkaisu › Pääkirjoitus › Tieteellinen
Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu
Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu
Heckman, C. (Projektinjohtaja), Adhikari, S. (osallistuja), Ikonen, N. (osallistuja), Kumari, R. (osallistuja), Mendoza Ortiz, E. D. (osallistuja), Newman, R. G. D. (osallistuja), Olgac, E. J. (osallistuja), Sergeev, P. (osallistuja), Srivastava, A. (osallistuja), Tambe, M. (osallistuja) & Tsallos, D. (osallistuja)
01/09/2023 → 31/08/2027
Projekti: Suomen Akatemia: Akatemiahanke
Heckman, C. (Projektinjohtaja), Ikonen, N. (osallistuja), Mendoza Ortiz, E. D. (osallistuja), Olgac, E. J. (osallistuja), Saad, J. (osallistuja), Suominen, P. L. J. (osallistuja), Tambe, M. (osallistuja) & Tsallos, D. (osallistuja)
Sigrid Juséliuksen Säätiö @003701165704@
01/05/2023 → 30/04/2026
Projekti: Rahastot ja säätiöt
Heckman, C. (Projektinjohtaja), Khabusheva, E. (osallistuja), Kumari, R. (osallistuja), Newman, R. G. D. (osallistuja), Saad, J. (osallistuja) & Srivastava, A. (osallistuja)
Suomen Akatemia Projektilaskutus
01/01/2023 → 31/12/2027
Projekti: Suomen Akatemia: Kahdenvälinen yhteistyö, yhteishaut
Heckman, C. (Projektinjohtaja), Adhikari, S. (osallistuja), Kallio, S. J. (osallistuja), Kuusanmäki, H. (osallistuja), Miettinen, J. (osallistuja), Olgac, E. J. (osallistuja), Parsons, A. O. (osallistuja), Ruokoranta, T. (osallistuja), Sergeev, P. (osallistuja) & Srivastava, A. (osallistuja)
National Institutes of Health (NIH) OFM
01/01/2023 → 31/12/2024
Projekti: Muu rahoittaja
Heckman, C. (Projektinjohtaja), Khabusheva, E. (osallistuja) & Olgac, E. J. (osallistuja)
01/12/2022 → 31/05/2023
Projekti: Yritysrahoitus
Liljeström, M. (Osallistuja), Mustjoki, S. (Osallistuja), Kontro, M. (Osallistuja), Heckman, C. (Osallistuja), Porkka, K. (Osallistuja), Klievink, J. (Osallistuja), Decombis, S. (Osallistuja), Miettinen, J. (Osallistuja), De Lorenzo, F. (Osallistuja) & Suvela, M. (Osallistuja)
Aktiviteetti: Muiden aktiviteettien tyypit › Muu
Heckman, C. (Jäsen)
Aktiviteetti: Jäsenyystyypit › Jäsenyys tai muu rooli arviointiryhmässä
Heckman, C. (Puhuja)
Aktiviteetti: Puhe- tai esitystyypit › Kutsuesitelmä
Heckman, C. (Puhuja)
Aktiviteetti: Puhe- tai esitystyypit › Kutsuesitelmä
Heckman, C. (Puhuja)
Aktiviteetti: Puhe- tai esitystyypit › Kutsuesitelmä